Baseline | End of 2-week run-in | After 2-week LED | End of trial | |||||
Number of participants reporting ≥1 symptom | 5 | 10 | 13 | 10 | ||||
Symptoms reported | N | %* | N | %* | N | %* | N | %* |
Nausea | 2 | 10.5 | 7 | 36.8 | 3 | 15.8 | 0 | 0.0 |
Vomiting | 1 | 5.3 | 1 | 5.3 | 0 | 0.0 | 0 | 0.0 |
Abdominal pain | 2 | 10.5 | 4 | 21.1 | 2 | 10.5 | 0 | 0.0 |
Diarrhoea | 3 | 15.8 | 5 | 26.3 | 6 | 31.6 | 0 | 0.0 |
Constipation | 1 | 5.3 | 0 | 0.0 | 4 | 21.1 | 1 | 5.3 |
Dizziness | 2 | 10.5 | 4 | 21.1 | 4 | 21.1 | 2 | 10.5 |
Heartburn | 0 | 0.0 | 2 | 10.5 | 1 | 5.3 | 0 | 0.0 |
Headaches | 2 | 10.5 | 5 | 26.3 | 3 | 15.8 | 3 | 15.8 |
Mood changes | 2 | 10.5 | 3 | 15.8 | 2 | 10.5 | 1 | 5.3 |
Cold sensitivity | 2 | 10.5 | 2 | 10.5 | 4 | 21.1 | 4 | 21.1 |
Hair loss | 1 | 5.3 | 0 | 0.0 | 2 | 10.5 | 3 | 15.8 |
Fatigue | 3 | 15.8 | 7 | 36.8 | 4 | 21.1 | 1 | 5.3 |
Total symptoms reported | 21 | 40 | 35 | 15 |
*Percentages calculated from total number of participants, not just of those reporting adverse effects.